nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2013 | short review

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

verfasst von: Thomas Melchardt, Lukas Weiss, Richard Greil, Priv. Doz. Alexander Egle, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Modern treatment strategies have resulted in an excellent overall survival in the majority of patients with Hodgkin’s lymphoma. PET-stratification is used to guide treatment in patients with limited disease in clinical trials, but recent results indicate that combined treatment with chemotherapy and radiotherapy is still the standard of care. Prediction of treatment related mortality and new data about chemotherapy induced infertility will guide our decisions especially in patients with advanced disease and brentuximab vedotin is now an approved option in patients with relapsed or refractory disease.

Vorheriger Artikel Georgia on my mind: multiple myeloma highlights at ASH 2012

Nächster Artikel Cancer-associated venous thromboembolism: risk assessment, prevention, and treatment

DeVita VT, Jr. A selective history of the therapy of Hodgkin’s disease. Br J Haematol. 2003;122(5):718–27.PubMedCrossRef

Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;11.

Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.PubMedCrossRef

Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.PubMedCrossRef

Wongso D, Plutschow A, Fuchs M, Haverkamp H, Klimm B, Sasse S, et al. Treatment-related mortality in patients undergoing therapy for advanced Hodgkin’s lymphoma: analysis of the German Hodgkin Study Group (GHSG). Onkologie. 2012;35:169–70.

Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, et al. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008;19(10):1795–801.PubMedCrossRef

Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9.PubMedCrossRef

Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010;28(34):5074–80.PubMedCrossRef

Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522–9.PubMedCrossRef

10.

Goda JS, Massey C, Kuruvilla J, Gospodarowicz MK, Wells W, Hodgson DC, et al. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys. 2012;84(3):e329–35.PubMedCrossRef

11.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMedCrossRef

12.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.PubMedCrossRef

13.

Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–81.PubMedCrossRef

14.

Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.PubMedCrossRef

Titel: What’s new in Hodgkin’s lymphoma: ASH 2012 and more
verfasst von: Thomas Melchardt
Lukas Weiss
Richard Greil
Priv. Doz. Alexander Egle, MD
Publikationsdatum: 01.09.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0095-7

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Radiofrequency ablation in gastrointestinal cancer: obstacles and goals

ASH 2012: “Helping hematologists conquer blood diseases worldwide”

Upper gastrointestinal cancer: POST ASCO 2013

Aggressive lymphoma at ASH 2012: new standards and new perspectives

Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

Biosimilars versus generics: scientific basics and clinical implications